Olink Proteomic Biomarker Discovery Tech Note

Proteomic Biomarker Discovery to Support Clinical Trials

Traditionally preclinical exploratory research and clinical trial biomarker detection and measurement have been restricted to a few indicators measured by mass spectrometry and ELISA (enzyme-linked immunosorbent assay). Using Olink® Proximity Extension Assay (PEA) technology, GENEWIZ from Azenta Life Sciences has deployed fully validated protein biomarker discovery services for higher-plex and scalable assays that have comparable sensitivity to traditional methods but utilize low sample amounts.

In this tech note, discover the science behind this assay and how its optimal approach makes it easier to incorporate protein biomarker discovery into your preclinical and clinical research.

What You'll Learn

• Discover the applications for high-plex proteomics
• The wide range of capabilities of multiplexed and high-plex Olink Target Panels
• The results of Azenta’s supplementary study on Olink Target 48 assay to characterize test performance